📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. (2020)

First Author: Poon E

Attributed to: Institute of Cancer Research Confidence in Concept (ICR CiC) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1172/jci134132

PubMed Identifier: 33016930

Publication URI: http://europepmc.org/abstract/MED/33016930

Type: Journal Article/Review

Volume: 130

Parent Publication: The Journal of clinical investigation

Issue: 11

ISSN: 0021-9738